# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Healthy Adults

> **NCT04629131** · PHASE1 · COMPLETED · sponsor: **Zhuhai Trinomab Pharmaceutical Co., Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Healthy Adult Subjects

## Interventions

- **BIOLOGICAL:** TNM002 Dosage 1 (10 μg/kg)
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** TNM002 Dosage 2 (35 μg/kg)
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** TNM002 Dosage 3 (100 μg/kg)
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** TNM002 Dosage 4 (250 μg/kg)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04629131
- **Lead sponsor:** Zhuhai Trinomab Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-25
- **Primary completion:** 2021-08-13
- **Final completion:** 2021-08-13
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2022-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04629131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04629131, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Healthy Adults". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04629131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*